{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:56:50Z","timestamp":1767135410836,"version":"build-2238731810"},"publisher-location":"Chichester, UK","reference-count":42,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd004315.pub2","type":"reference-entry","created":{"date-parts":[[2005,1,17]],"date-time":"2005-01-17T02:17:07Z","timestamp":1105928227000},"source":"Crossref","is-referenced-by-count":6,"title":["Botulinum toxin type B for cervical dystonia"],"prefix":"10.1002","author":[{"given":"Jo\u00e3o","family":"Costa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e1udia C","family":"Esp\u00edrito-Santo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana A","family":"Borges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquim","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel M","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Sampaio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,10,18]]},"reference":[{"key":"10.1002\/14651858.CD004315.pub2-BIB1|cit1","first-page":"A292 (S46.003)","article-title":"Safety and efficacy of NeuroBloc (Botulinum toxin type B) in type A-responsive cervical dystonia","volume":"52 (Suppl 2)","author":"Brashear","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004315.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1212\/WNL.53.7.1439","article-title":"Safety and efficacy of NeuroBloc (Botulinum toxin type B) in type A-responsive cervical dystonia","volume":"53(7)","author":"Brashear","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004315.pub2-BIB4|cit3","series-title":"Toxins'99 (www.wemove.org)","first-page":"9","article-title":"Safety and efficacy of Neurobloc (Botulinum toxin type-B) in type-A responsive and type-A resistant patients with cervical dystonia","author":"Factor"},{"key":"10.1002\/14651858.CD004315.pub2-BIB3|cit4","first-page":"7","article-title":"Safety and efficacy of Neurobloc (Botulinum toxin type-B) in type-A responsive and type-A resistant patients with cervical dystonia","volume":"15 (Suppl 2)","author":"Factor","year":"2000","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004315.pub2-BIB5|cit5","first-page":"31","article-title":"Evaluation of Neurobloc (Botulinum toxin type B) efficacy in patients with cervical dystonia","volume":"15 (Suppl 2)","author":"Koller","year":"2000","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004315.pub2-BIB6|cit6","first-page":"S29","article-title":"The safety and efficacy of Botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials","volume":"55 (Suppl 5)","author":"Lew","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004315.pub2-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1212\/WNL.53.7.1431","article-title":"Safety and efficacy of NeuroBloc (Botulinum toxin type B) in type A-resistant cervical dystonia","volume":"22;53(7)","author":"Brin","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004315.pub2-BIB8|cit8","first-page":"A293 (S46.004)","article-title":"Safety and efficacy of NeuroBloc (Botulinum toxin type B) in type A-resistant cervical dystonia","volume":"52 (Suppl 2)","author":"Brin","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004315.pub2-BIB10|cit9","first-page":"9","article-title":"Safety and efficacy of Neurobloc (Botulinum toxin type-B) in type-A responsive and type-A resistant patients with cervical dystonia","author":"Factor","journal-title":"Toxins'99 (www.wemove.org)"},{"key":"10.1002\/14651858.CD004315.pub2-BIB9|cit10","first-page":"7","article-title":"Safety and Efficacy of Neurobloc (Botulinum Toxin Type-B) in Type-A Responsive and Type-A Resistant Patients with Cervical Dystonia","volume":"15 (Suppl 2)","author":"Factor","year":"2000","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004315.pub2-BIB11|cit11","series-title":"Mov Disord","first-page":"31","article-title":"Evaluation of Neuroblocc (Botulinum Toxin Type B) Efficacy in Patients With Cervical Dystonia","author":"Koller","year":"2000"},{"key":"10.1002\/14651858.CD004315.pub2-BIB12|cit12","first-page":"S29","article-title":"The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials","volume":"55 (Suppl 5)","author":"Lew","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004315.pub2-BIB13|cit13","first-page":"31","article-title":"Evaluation of Neuroblocc (Botulinum toxin type B) efficacy in patients with cervical dystonia","volume":"15 (Suppl 2)","author":"Koller","year":"2000","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004315.pub2-BIB14|cit14","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1212\/WNL.49.3.701","article-title":"Botulinum toxin type B: A double-blind, placebo controlled, safety and efficacy study in cervical dystonia","volume":"49","author":"Lew","year":"1997","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004315.pub2-BIB15|cit15","first-page":"S29","article-title":"The safety and efficacy of Botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials","volume":"55 (Suppl 5)","author":"Lew","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004315.pub2-BIB16|cit16","first-page":"2874 (abstract)","article-title":"BotB (Botulinum toxin type B) in the treatment of cervical dystonia (CD) - protocol AN072-008: an interim analysis","volume":"10","year":"1995","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004315.pub2-BIB17|cit17","first-page":"31","article-title":"Evaluation of Neuroblocc (Botulinum toxin type B) efficacy in patients with cervical dystonia","volume":"15 (Suppl 2)","author":"Koller","year":"2000","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004315.pub2-BIB18|cit18","first-page":"29","article-title":"Safety and tolerability of repeated doses of Neurobloc (Botulinum toxin type B) in patients with cervical dystonia: an open-label, dose-escalation study","volume":"15 (Suppl 2)","author":"Cullis","year":"2000","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004315.pub2-BIB19|cit19","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/mds.870120526","article-title":"BotB (Botulinum Toxin Type B): Evaluation of safety and tolerability in Botulinum type A-resistant cervical dystonia aatients (Preliminary Study)","volume":"12(5)","author":"Truong","year":"1997","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004315.pub2-BIB20|cit20","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1136\/bmj.313.7055.486","article-title":"Statistics notes. Interaction 1: Heterogeneity of effects","volume":"313(7055)","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004315.pub2-BIB21|cit21","article-title":"Meta-analysis, Simpson's paradox, and the number needed to treat","volume":"2(1):3. Epub 20","author":"Altman","year":"2002","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD004315.pub2-BIB22|cit22","volume-title":"Scientific and Therapeutic Aspects of Botulinum Toxin","author":"Brin","year":"2002"},{"key":"10.1002\/14651858.CD004315.pub2-BIB23|cit23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/mds.870060206","article-title":"Idiopathic cervical dystonia: clinical characteristics","volume":"6","author":"Chan","year":"1991","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004315.pub2-BIB24|cit24","first-page":"29","article-title":"Botulinum toxin type A for the treatment of cervical dystonia: a systematic review","volume":"15 (Suppl 3)","author":"Costa","year":"2000","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004315.pub2-BIB25|cit25","first-page":"227","article-title":"Botulinum toxin type B: an open-label, dose-escalation, safety and preliminary efficacy study in cervical dystonia patients","volume":"78","author":"Cullis","year":"1998","journal-title":"Advances in Neurology"},{"key":"10.1002\/14651858.CD004315.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0304-3940(97)13448-6","article-title":"Botulinum neurotoxin serotype C: a novel effective botulinum toxin therapy in human","volume":"224(2)","author":"Eleopra","year":"1997","journal-title":"Neuroscience Letters"},{"key":"10.1002\/14651858.CD004315.pub2-BIB27|cit27","first-page":"787","article-title":"The Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group","volume":"247","author":"ESDE","year":"2000","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD004315.pub2-BIB28|cit28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3171\/jns.1959.16.1.0055","article-title":"Experimental spasmodic torticollis","volume":"16","author":"Foltz","year":"1959","journal-title":"Journal of Neurosurgery"},{"key":"10.1002\/14651858.CD004315.pub2-BIB29|cit29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/mds.870090216","article-title":"Development of resistance to botulinum toxin type A in patients with torticollis","volume":"9(2)","author":"Greene","year":"1994","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004315.pub2-BIB30|cit30","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/mds.870080411","article-title":"Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A","volume":"8(4)","author":"Greene","year":"1993","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004315.pub2-BIB31|cit31","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/archneur.1990.00530050070014","article-title":"Natural history of adult-onset idiopathic torticollis","volume":"47","author":"Jahnanshani","year":"1990","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD004315.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1212\/WNL.41.7.1088","article-title":"Cervical dystonia: clinical findings and associated movement disorders","volume":"41","author":"Jankovic","year":"1991","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD004315.pub2-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1001\/archneur.1991.00530240057020","article-title":"Clinical correlates of response to botulinum toxin injections","volume":"48(12)","author":"Jankovic","year":"1991","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD004315.pub2-BIB34|cit34","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00415-003-0942-2","article-title":"Abnormalities of cortical excitability and cortical inhibition in cervical dystonia Evidence from somatosensory evoked potentials and paired transcranial magnetic stimulation recordings","volume":"250(1)","author":"Kanovsky","year":"2003","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD004315.pub2-BIB35|cit35","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1126\/science.1067300","article-title":"Midbrain control of three-dimensional head orientation","volume":"295(5558)","author":"Klier","year":"2002","journal-title":"Science"},{"key":"10.1002\/14651858.CD004315.pub2-BIB36|cit36","doi-asserted-by":"crossref","unstructured":"Kreyden O.P Botulinum Toxin: From Poison to Pharmaceutical The History of a Poison That Became Useful to Mankind In Kreyden OP, B\u00f6ni R, Burg G (eds): Hyperhidrosis and Botulinum Toxin in Dermatology Curr Probl Dermatol. Basel, Karger, 2002, vol 30, pp 94-100.","DOI":"10.1159\/000060669"},{"key":"10.1002\/14651858.CD004315.pub2-BIB37|cit37","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/mds.870030302","article-title":"Epidemiology of focal and generalized dystonia in Rochester, Minnesota","volume":"3(3)","author":"Nutt","year":"1988","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004315.pub2-BIB38|cit38","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1136\/bmj.318.7197.1548","article-title":"Numbers needed to treat derived from meta-analysis - sometimes informative, usually misleading","volume":"318(7197)","author":"Smeeth","year":"1999","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD004315.pub2-BIB39|cit39","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/mds.870120117","article-title":"Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin","volume":"12","author":"Tarsy","year":"1997","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD004315.pub2-BIB40|cit40","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(86)92070-2","article-title":"Double-blind study of botulinum toxin in spasmodic torticollis","volume":"ii","author":"Tsui","year":"1986","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD004315.pub2-BIB41|cit41","first-page":"211","volume-title":"Clinical assessments of patients with cervical dystonia","author":"Consky","year":"1994"},{"key":"10.1002\/14651858.CD004315.pub2-BIB42|cit42","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1212\/WNL.43.9.1715","article-title":"Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance","volume":"43(9)","author":"Zuber","year":"1993","journal-title":"Neurology"}],"updated-by":[{"DOI":"10.1002\/14651858.cd004315.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T00:00:00Z","timestamp":1463097600000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD004315.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T07:49:48Z","timestamp":1705736988000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD004315.pub2"}},"subtitle":[],"editor":[{"given":"Jo\u00e3o","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2004,10,18]]},"references-count":42,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004315.pub2","relation":{},"subject":[],"published":{"date-parts":[[2004,10,18]]}}}